Typicality: | 0.314 |
Saliency: | 0.340 |
in the 1997 meeting | 4 | temporal |
to issue a safety advisory | 3 | purpose |
concern → be raised by → the fda | 8 |
concern → prompt → the fda | 5 |
concern → be raised by → fda | 5 |
concern → be expressed by → the fda | 5 |
negative | neutral | positive |
0.361 | 0.556 | 0.083 |
Raw frequency | 23 |
Normalized frequency | 0.340 |
Modifier score | 0.250 |
Perplexity | 23.899 |